Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No	Serial No.
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	C-3169/1/US	09/451,641
	Applicant: Gao, D. *et al.*	
	Filing Date: November 30, 1999	Group No: 1615

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant	Class	Subclass	Filing Date if Appropriate
S.T		4,895,726	Jan 23, 1990	Curtet *et al*	424	456	

FOREIGN PATENT DOCUMENTS

Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant	Class	Subclass	Translation Yes	Translation No
S.T		EP 0 001 247	Apr 4, 1979	Kanebo	A61K	9/18		
		EP 0 256 933	Feb 24, 1988	Ethypharm	A61K	31/235		X
		EP 0 330 532	Aug 30, 1989	Fournier Industrie et Santé	A61K	9/16		X
		WO 96/38131	Dec 5, 1996	Glaxo	A61K	9/14		
S.T		WO 00/15195	Mar 23, 2000	Nycomed	A61K	9/16		

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

S.T		Amidon *et al.* (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. *Pharmaceutical Research* 12(3), 413-420.
		Ansel (1985) *Introduction to Pharmaceutical Dosage Forms*, 4th ed. Philadelphia: Lea & Febiger. Page cited: vii (first page of Contents).
		Aulton, ed. (1988) *Pharmaceutics: The Science of Dosage Form Design*. Edinburgh: Churchill Livingstone. Pages cited: 8, 156, 311, 330.
		Basit *et al.* (2001) The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the fromulation of poorly water-soluble drugs. *Pharmaceutical Research* 18(8), 1146-1150.
		Bauer *et al.* (1991) *Pharmazeutische Technologie*, 3rd ed. Stuttgart: Verlag. Pages cited: 104, 203.
		Berry & Nash, ed. (1993) *Pharmaceutical Process Validation*, 2nd ed. New York: Marcel Dekker. Pages cited: 174–181.
		British Pharmacopoeia 1993. Pages cited: Vol. I, 316; Vol. II, 753
		Fincher *et al.* (1965) Effect of particle size on gastrointestinal absorption of sulfisoxazole in dogs. *J. Pharm. Sci.* 54(5), 704-708.
		Ghosh *et al.* (1998) Product development studies on the tablet formulation of ibuprofen to improve bioavailability. *Drug Development & Industrial Pharmacy* 24(5), 473-477
		Gibaldi (1991) *Biopharmaceutics and Clinical Pharmacokinetics*, 4th ed. Philadelphia: Lea & Febiger. Pages cited: 51, 52, 62
		Hubbard *et al.* (1996) SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute non-surgical pain model. *J. Invest. Med.* 44(3), 293A.
S.T		Hubbard *et al.* (1996) SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. *Arthritis & Rheumatism* 39 (Suppl. 9), S226, abstract 1188

Examiner	Date Considered
S.T	11/12/03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. C-3169/1/US	Serial No 09/451,641
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Gao, D. *et al.*	
	Filing Date November 30, 1999	Group No 1615

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

S.T			Hubbard *et al.* (1997) Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis *Arthritis & Rheumatism* 40, S51, abstract 125.
			Kaneniwa *et al.* (1973) Dissolution of slightly soluble drugs. I Influence of particle size on dissolution behavior *Chem. Pharm. Bull.* 22(8), 1699–1705.
			Kaneniwa *et al.* (1978) Dissolution of slightly soluble drugs IV. Effect of particle size of sulfonamides on *in vitro* absorption rate, and their relation to solubility. *Chem. Pharm. Bull.* 26(3), 813–826.
			Lachman *et al.*, ed. (1986) *The Theory and Practice of Industrial Pharmacy*, 3rd ed. Philadelphia: Lea & Febiger. Pages cited: 21–45, 321–328.
			Levy (1963). Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. *Amer. J. Pharm.*, March 1963, 78–92.
			List (1985) *Arzneiformenlehre*, 4th ed. Stuttgart: Wissenschaftliche Verlagegesellschaft. Pages cited: 210, 523.
			Martin (1993) *Physical Pharmacy*, 4th ed. Philadelphia: Lea & Febiger. Pages cited: 331, 423–436.
			Ridolfo *et al.* (1979) Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. *J. Pharm. Sci.* 68(7), 850–852.
			Sprowls (1963) *Prescription Pharmacy*. Philadelphia: Lippincott. Page cited: 56.
			Voigt (1984) *Lehrbuch der Pharmazeutischer Technologie*, 5th ed. Basel: Verlag. Pages cited: 471, 472, 637.
			Wade & Weller (1994) *Handbook of Pharmaceutical Excipients*, 2nd ed. Washington: American Pharmaceutical Association. Pages cited: v, vi (Contents pages), 141, 163, 252, 280, 433, 448.
			Wadke *et al.* (1989) Preformulation testing. In Lieberman *et al.*, ed.: *Pharmaceutical Dosage Forms: Tablets*, Vol. 1. New York: Marcel Dekker. Pages cited: 5,6.
S.T			Zhao *et al.* (1997) Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. *Arthritis & Rheumatism* 40 (Suppl. 9), S88, abstract 348.

Examiner	Date Considered
S.T	11/12/03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.